Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

医学 托法替尼 耐受性 内科学 不利影响 关节炎 痹症科 外科 类风湿性关节炎
作者
Hermine I. Brunner,Jonathan Akikusa,Eslam Al‐Abadi,John F. Bohnsack,Alina Boteanu,Gaëlle Chédeville,Rubén Cuttica,Wendy de la Pena,Lawrence Jung,Ela Tarakçı,Katarzyna Kobusińska,Grant S. Schulert,Cláudia Lopes Santoro Neiva,Rafael Rivas‐Chacon,Juan Cruz Rizo Rodriguez,Mónica Vázquez-Del Mercado,Linda Wagner‐Weiner,Jennifer E. Weiss,Carine Wouters,Holly Posner,Ann Wouters,Cheng Chang,Claire White,Keith S. Kanik,Shixue Liu,Alberto Martini,Daniel J. Lovell,Nicolino Ruperto
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: ard-225094 被引量:1
标识
DOI:10.1136/ard-2023-225094
摘要

Objectives We report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study. Methods Patients (2–<18 years) with JIA who completed phase 1/3 index studies or discontinued for reasons excluding treatment-related serious adverse events (AEs) entered the LTE study and received tofacitinib 5 mg two times per day or equivalent weight-based doses. Safety outcomes included AEs, serious AEs and AEs of special interest. Efficacy outcomes included improvement since tofacitinib initiation per the JIA-American College of Rheumatology (ACR)70/90 criteria, JIA flare rate and disease activity measured by Juvenile Arthritis Disease Activity Score (JADAS)27, with inactive disease corresponding to JADAS ≤1.0. Results Of 225 patients with JIA (median (range) duration of treatment, 41.6 (1–103) months), 201 (89.3%) had AEs; 34 (15.1%) had serious AEs. 10 patients developed serious infections; three had herpes zoster. Two patients newly developed uveitis. Among patients with polyarticular course JIA, JIA-ACR70/90 response rates were 60.0% (78 of 130) and 33.6% (47 of 140), respectively, at month 1, and generally improved over time. JIA flare events generally occurred in <5% of patients through to month 48. Observed mean (SE) JADAS27 was 22.0 (0.6) at baseline, 6.2 (0.7) at month 1 and 2.8 (0.5) at month 48, with inactive disease in 28.8% (36 of 125) of patients at month 1 and 46.8% (29 of 82) at month 48. Conclusions In this interim analysis of LTE study data in patients with JIA, safety findings were consistent with the known profile of tofacitinib, and efficacy was maintained up to month 48. Trial registration number NCT01500551 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助火星上念梦采纳,获得10
刚刚
聪明无敌小腚宝完成签到,获得积分10
1秒前
虚心求学完成签到,获得积分10
1秒前
Owen应助<小天才>采纳,获得10
4秒前
英姑应助九思采纳,获得10
5秒前
6秒前
6秒前
6秒前
7秒前
量子星尘发布了新的文献求助10
8秒前
JamesPei应助机灵的囧采纳,获得10
9秒前
llll发布了新的文献求助10
9秒前
orixero应助xmh采纳,获得10
9秒前
wq1020发布了新的文献求助10
11秒前
12秒前
皮皮蛙完成签到,获得积分10
12秒前
情怀应助常芹采纳,获得10
13秒前
肖肖发布了新的文献求助10
13秒前
13秒前
13秒前
14秒前
缥缈问柳完成签到,获得积分10
14秒前
14秒前
明理念桃完成签到,获得积分10
15秒前
13333发布了新的文献求助10
16秒前
Ava应助不吃意面的老番茄采纳,获得10
18秒前
18秒前
zhao完成签到 ,获得积分10
20秒前
21秒前
21秒前
21秒前
xmh完成签到,获得积分10
22秒前
什么也难不倒我完成签到 ,获得积分10
22秒前
23秒前
孟一发布了新的文献求助30
23秒前
24秒前
小幻完成签到,获得积分10
24秒前
好宝宝发布了新的文献求助10
25秒前
25秒前
乐天完成签到,获得积分10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028